Mefac (Mefenamic Acid)

Mefenamic acid works by reversibly inhibiting the cyclooxygenase‑1 and cyclooxygenase‑2 enzymes, which are essential for converting arachidonic acid into prostaglandins. Lower prostaglandin levels reduce peripheral sensitisation of pain receptors and diminish inflammation, providing both analgesic and anti‑inflammatory effects.

The appropriate dose of Mefac is determined by the prescribing healthcare professional based on the individual’s condition, age, weight, and response to therapy. Patients should follow the prescriber’s instructions and not adjust the dose without medical guidance.

Safety data for mefenamic acid in pregnancy and lactation are limited. It is generally advised to avoid use during the first trimester and to discuss potential risks with a healthcare provider. Breastfeeding mothers should also seek medical advice before using Mefac.

To request Mefac, submit an enquiry on the product page at gnhindia.com, specifying the required quantity. GNH India works with hospitals, pharmacies, and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details and any necessary import documentation.

Both Mefac (mefenamic acid) and ibuprofen belong to the NSAID class and share similar mechanisms of COX inhibition. Mefac is often chosen for its efficacy in dysmenorrhea, whereas ibuprofen is widely used for a broader range of pain types. Individual response, safety profile and physician preference guide the selection.

Mefac should be stored at ambient temperature, preferably below 25 °C, in its original packaging to protect it from moisture and direct sunlight. Keep the product out of reach of children and avoid storing it in bathrooms or other humid environments.

Mefac is taken orally, usually with a full glass of water. It may be taken with or without food, but taking it with food can help reduce gastrointestinal discomfort. Patients should swallow the tablet whole and not crush or chew it unless directed by a healthcare professional.

Serious risks include gastrointestinal bleeding or ulceration, severe hypersensitivity reactions such as Stevens‑Johnson syndrome, renal impairment, and hepatotoxicity. Patients should be monitored for signs of bleeding, rash, jaundice, or sudden changes in kidney function, and seek immediate medical attention if these occur.

Mefac is contraindicated in individuals with known hypersensitivity to mefenamic acid or other NSAIDs, active peptic ulcer disease, severe heart failure, uncontrolled hypertension, and those who have experienced serious gastrointestinal bleeding. It should also be avoided in patients with severe renal or hepatic impairment unless specifically directed by a physician.